May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC
November 21st 2022During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Read More
Cemiplimab Makes Case as First-Line, Nonchemotherapy Treatment in Metastatic NSCLC
November 18th 2022Updated results of the EMPOWER-Lung1 trial of cemiplimab in patients advanced or metastatic non–small cell lung cancer showed improvements in overall survival, progression-free survival, and overall response rate.
Read More
Reflex Testing of Next Generation Sequencing (NGS)-Based Panels in NSCLC
Nurse Practitioner Lauren Welch and Dr Michelle Shiller share whether next-generation sequencing is reflexively ordered at their institutions, turnaround times for this type of testing, and which panels they typically choose.
Watch
Broad Molecular Testing Use in Adenocarcinoma versus Squamous Cell Carcinoma
Drs Shiller and Piotrowska discuss use of broad genomic profiling according to the patient’s histologic subtype of NSCLC.
Watch
Choosing Early-Line Therapy for NSCLC With an EGFR Exon 20 Insertion
November 16th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Read More
Unknown Long-Term Effects of E-Cigarettes Generates Questions in Lung Cancer
November 16th 2022While information has come out stating the negative effects of e-cigarettes on lung health, questions regarding the longer-term safety of these products remain due to their limited timespan on the market.
Read More
Roundtable Discussion: The Role of Adjuvant Therapies for NSCLC Based on Disease Stage
November 14th 2022During a Targeted Oncology case-based roundtable event, Joel Neal, MD, PhD, and Leah Backhus, MD, MPH, discussed adjuvant therapies including chemotherapy, immunotherapy, and targeted therapy for patients with non–small cell lung cancer.
Read More
FDA Approves Tremelimumab With Durvalumab and Platinum Chemotherapy for mNSCLC
November 10th 2022The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.
Read More
A Commentary on High PD-L1 Expression in NSCLC
Lauren Welch, MSN, NP-C, AOCNP, describes how she approaches management of patients with NSCLC and known high PD-L1 expression while she waits for pending biomarker testing results.
Watch
Biomarkers and Biomarker Testing in NSCLC
Zosia Piotrowska, MD, and Michelle Shiller, DO, AP/CP, MGP, explain the frequency of the different biomarkers in NSCLC, and steps clinicians might take to ensure timely and effective molecular testing for their patients.
Watch
In the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Read More
Roundtable Discussion: Salgia Looks at Testing and Treatment for NSCLC With EGFR Exon 20 Insertions
November 8th 2022During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.
Read More
Frontline Pembrolizumab Monotherapy Continues to Elicit Clinical Benefit vs Chemo in NSCLC
November 7th 2022Five-year data from the phase 3 KEYNOTE-042 shows that patients with non–small cell lung cancer without EGFR/ALK alterations continue to elicit durable benefit with pembrolizumab monotherapy vs chemotherapy.
Read More